Logo of Herbal Extract
  • Home
  • About Us
  • Categories ▼
    • Reference Substances
    • Botanical Ingredient
    • Standard Herbal Extract
    • ► Hot Product
  • Applications
  • Inquiry
  • FAQ
  • Contact Us
  • Popular Searches:
  • Artemisinin
  • ,
  • Betulinic Acid
  • ,
  • Apigenin
  • ,
  • Arbutin
  • ,
  • Deoxyarbutin
  • ,
  • Diosgenin
  • ,
  • Kaempferol
  • ,
  • Resveratrol
  • ,
  • Green Coffee Bean Extract
  • ,
  • Banaba Leaf Extract
  • ,
  • Loquat Leaves Extract
CATEGORIES
  • Reference Substances

  • Botanical Ingredient

  • Standard Herbal Extract

CONTACT US
  • Contact for herbal and plant extracts
KNOWLEDGE
  • Can Sesamin be an ideal cure to obesity?
  • Berberine for Overall Wholeness and Wellness
  • Artemether Treats Malaria in Both Adults and Children
  • Side Effects and Cautions in Artemisinins Applications
  • Artemisinin Resistance Can Be Defeated By Drug Combinations
Home » Products » Botanical Ingredient » Paclitaxel (Taxol)

Paclitaxel (Taxol)

Chemical Structure of Paclitaxel (Taxol)

Paclitaxel (Taxol) is extracted from Taxaceae. Stanford Chemicals has been providing quality Paclitaxel (Taxol) and many other natural plant extract for over 15 years.

Product Name

Paclitaxel (Taxol)

CAS No.

33069-62-4

Molecular Formula

C47H51NO14

Molecular Weight

853.91

Botanical Source

Taxaceae

Purity

98% HPLC

Appearance

White powder

Package

25 kg/drum

Storage

Stored in cool & dry places, protected from direct sunlight and heat.

Shelf Life

2 years

Paclitaxel (Taxol) Safety Tips

Handling of Paclitaxel (Taxol) should only be performed by personnel trained and familiar with handling of potent active pharmaceutical ingredients. Moderate to severe irritant to the skin and eyes.

References
  • 1. Synthesis and Biological Evaluation of a Biotinylated Paclitaxel With an Extra-Long Chain Spacer Arm.

    Lis LG, Smart MA, Luchniak A, Gupta ML Jr, Gurvich VJ.ACS Med Chem Lett. 2012 Sep 13;3(9):745-748. Epub 2012 Jul 30.

  • 2. Qualitative and Quantitative Assessment of Stent Restenosis by Optical Coherence Tomography.

    Nagoshi R, Shinke T, Otake H, Shite J, Matsumoto D, Kawamori H, Nakagawa M, Kozuki A, Hariki H, Inoue T, Ohsue T, Taniguchi Y, Iwasaki M, Nishio R, Hiranuma N, Konishi A, Kinutani H, Miyoshi N, Takaya T, Yamada S, Yasaka Y, Hayashi T, Yokoyama M, Kato H, Kadotani M, Ohnishi Y, Hirata KI.Circ J. 2012 Dec 21. [Epub ahead of print]

  • 3. Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy: Case report and review of the literature.

    Funakoshi S, Hashiguchi A, Teramoto K, Miyata N, Kurita S, Adachi M, Hamamoto Y, Higuchi H, Takaishi H, Hibi T.Oncol Lett. 2013 Jan;5(1):117-122. Epub 2012 Oct 30.

  • 4. Acute and long-term angiographic outcomes of side branch stenosis after randomized treatment of zotarolimus-, sirolimus-, and Paclitaxel-eluting stent for coronary artery stenosis.

    Lee BK, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, Lee JY, Kim WJ, Kang SJ, Lee SW, Lee CW, Lee JH, Seong IW, Park SW, Park SJ.J Korean Med Sci. 2012 Dec;27(12):1499-506. doi: 10.3346/jkms.2012.27.12.1499. Epub 2012 Dec 7.

  • 5. Lung cancer and pregnancy.

    Sar?man N, Levent E, Yener NA, Orki A, Sayg? A.Lung Cancer. 2012 Dec 14. doi:pii: S0169-5002(12)00635-6.  10.1016/j.lungcan.2012.11.014. [Epub ahead of print]

  • 6. Efficacy and toxicity differences in lung cancer populations in the era of clinical trials globalization: the 'common arm' approach.

    Mack PC, Gandara DR, Lara PN Jr.Expert Rev Anticancer Ther. 2012 Dec;12(12):1591-6. doi: 10.1586/era.12.135.

  • 7. Mechanistic Study of Covalent Loading of Paclitaxel via Disulfide Linkers for Controlled Drug Release.

    Yuan L, Chen W, Hu J, Zhang JZ, Yang D.Langmuir. 2012 Dec 19. [Epub ahead of print]

  • 8. Praziquantel synergistically enhances Paclitaxel efficacy to inhibit cancer cell growth.

    Wu ZH, Lu MK, Hu LY, Li X.PLoS One. 2012;7(12):e51721. doi: 10.1371/journal.pone.0051721. Epub 2012 Dec 12.

  • 9. Update on taxane development: new analogs and new formulations.

    Yared JA, Tkaczuk KH.Drug Des Devel Ther. 2012;6:371-84. doi: 10.2147/DDDT.S28997. Epub 2012 Dec 11.

  • 10. Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer.

    Noronha V, Patil V, Ostwal V, Tongaonkar H, Bakshi G, Prabhash K.Urol Ann. 2012 Sep;4(3):150-3. doi: 10.4103/0974-7796.102659.

  • 11. Weekly paclitaxel in escalating doses in a patient with anthracycline-resistant, triple-negative, metastatic breast cancer with severe liver dysfunction.

    Gupta A.Indian J Med Paediatr Oncol. 2012 Jul;33(3):170-2. doi: 10.4103/0971-5851.103145.

  • 12. Phase III Trial of Carboplatin and Paclitaxel With or Without Sorafenib in Metastatic Melanoma.

    Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM.J Clin Oncol. 2012 Dec 17. [Epub ahead of print]

  • 13. Complete Response to Second Line Paclitaxel Every 2 Weeks of Eyelid Kaposi Sarcoma:  A Case Report.

    Brunetti AE, Attilio G, Vito L, Carla M, Angela S, Ilaria M, Nicola S.Ophthal Plast Reconstr Surg. 2012 Dec 14. [Epub ahead of print]

  • 14. Poly(ethylene glycol)-block-poly(ε-caprolactone) Micelles for Combination Drug Delivery: Evaluation of Paclitaxel, Cyclopamine and Gossypol in Intraperitoneal Xenograft Models of Ovarian Cancer.

    Cho H, Lai TC, Kwon GS.J Control Release. 2012 Dec 12. doi:pii: S0168-3659(12)00832-2.  10.1016/j.jconrel.2012.12.005. [Epub ahead of print]

  • 15. Gemcitabine Plus Paclitaxel as Second-line Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer.

    Baykara M, Coskun U, Berk V, Ozkan M, Kaplan MA, Benekli M, Karaca H, Inanc M, Isikdogan A, Sevinc A, Elkiran ET, Demirci U, Buyukberber S.Asian Pac J Cancer Prev. 2012;13(10):5119-24.

  • 16. An Association between Bevacizumab and Recurrent Posterior Reversible Encephalopathy Syndrome in a Patient Presenting with Deep Vein Thrombosis: A Case Report and Review of the Literature.

    Lazarus M, Amundson S, Belani R.Case Rep Oncol Med. 2012;2012:819546. doi: 10.1155/2012/819546. Epub 2012 Nov 29.

  • 17. Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice.

    van de Steeg E, van Esch A, Wagenaar E, Kenworthy KE, Schinkel AH.Clin Cancer Res. 2012 Dec 14. [Epub ahead of print]

  • 18. Three-year follow-up after treatment of bare-metal stent restenosis with first-generation or second-generation drug-eluting stents.

    Almalla M, Schröder JW, Pross V, Marx N, Hoffmann R.Coron Artery Dis. 2012 Dec 13. [Epub ahead of print]

  • 19. Sensitivity and mechanisms of taxol-resistant prostate adenocarcinoma cells to Vernonia amygdalina extract.

    Cameron KS, Howard CB, Izevbigie EB, Hill BJ, Tchounwou PB.Exp Toxicol Pathol. 2012 Dec 10. doi:pii: S0940-2993(12)00108-X.  10.1016/j.etp.2012.11.002. [Epub ahead of print]

  • 20. Adjuvant chemotherapy with six cycles of AC regimen versus three cycles of AC regimen followed by three cycles of Paclitaxel in node-positive breast cancer.

    Roy C, Choudhury KB, Pal M, Saha A, Bag S, Banerjee C.Indian J Cancer. 2012 Jul;49(3):266-71. doi: 10.4103/0019-509X.104483.

Back to top
  • About Us
  • Terms & Conditions
  • Sitemap
  • Contact Us
  • Friendlink
  • Products
Logo of Plant Ingredient
Copyright © 1994-2013 Stanford Chemicals, All Rights Reserved.